The FDA's Oncology Center of Excellence and Syapse presented data at the American Association of Clinical Research COVID-19 and Cancer meeting on an analysis of more than 212,000 health records of people living with cancer across two major health systems in the Midwestern United States.
An updated cervical cancer screening guideline from the American Cancer Society reflects the rapidly changing landscape of cervical cancer prevention in the United States, calling for less and more simplified screening.
Researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute and The Ohio State University Wexner Medical Center are conducting a clinical trial to determine if ibrutinib (Imbruvica) can help patients with cancer or other immunocompromised conditions recover from COVID-19.
Researchers at Fox Chase Cancer Center found that older patients who underwent chemoradiation therapy followed by removal of their esophagus due to cancer had toxicities and outcomes similar to younger patients.
A study by UPMC and University of Pittsburgh School of Medicine researchers demonstrates the highest accuracy to date in recognizing and characterizing prostate cancer using an artificial intelligence program.
Researchers at the University of Arizona Health Sciences have developed a handheld device to bring skin cancer prevention and treatment options into more patient-care settings.
The American College of Surgeons Cancer Programs developed the Cancer Surgery Standards Program, a new program that aims to improve the quality of surgical care provided to cancer patients by implementing standards for cancer surgery and standardizing the way operative data are documented and communicated.
St. Jude Children's Research Hospital scientists have developed a computational tool to identify alterations that drive tumor formation in 98% of the genome. Gene coding regions constitute 2% of the human genome.
The National Comprehensive Cancer Network has created the NCCN Distress Thermometer to help providers identify and address the multifactorial aspects of distress cancer patients can experience.
Scientists at the Wellcome Sanger Institute, EMBL's European Bioinformatics Institute and AstraZeneca combined drug response data with CRISPR genetic screens across hundreds of cancer cell lines to better understand how drugs target cancer cells.